But Denner already knew about the patent loss and China as well. Operating losses are just a management issue, so that wasn't a big "surprise" in terms of Denner's investment thesis.
Germany was probably a punch in the gut, but not terminal.
And I'm sure he is well aware the time and cost involved in rolling a drug out in Europe and other countries.
My guess is that he probably has a different view on capital deployment - specifically related to getting revenue generated overseas as quickly as possible, so making sure they are deploying capital in the right places. One of the things he has talked about is their lack of "speed" or "sense of urgency".
In my honest opinion, I don't think Amarin management is "arrogant" or "selfish", or whatever. I think they are just in over their heads with the overseas rollout, at a moment when they need MORE support and are trying to REDUCE expenses at the same time. It's a bad recipe. And I think Denner is focusing on this.
News 
Market Data 
Discover 
